EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer Vaccine and Therapy

Shengnan Huang iD, Yanpu He, Allison Madow, Huaiyao Peng, Mirielle Griffin, Jifa Qi, Mantao Huang iD, Heather Amoroso, Riley Abrashoff, Nimrod Heldman, Angela M Belcher iD

Advanced Materials · 2025-10 · 37 (43)

DOI: 10.1002/adma.202510229 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 27.08.2025. Verfasst von Shengnan Huang und 10 weiteren Autor:innen. Beteiligte Einrichtung: The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA. Hauptthemen laut MEDLINE: Cancer Vaccines, Bacteriophage M13, Precision Medicine, Nanoparticles. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Koch Institute Frontier Research Program, Defense Advanced Research Projects Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nanovaccines co‐assemble antigens and adjuvants to elicit robust immune responses but often require complex synthesis and post‐modification procedures. Here, a programmable nanovaccine platform based on the M13 bacteriophage is developed for the scalable production of vaccines and single‐step modular engineering of adjuvanticity, length, and antigen density. By reprogramming the sequence and size of the noncoding phage genome, the Toll‐like receptor 9 activation and the length of the phage are precisely controlled. With a novel molecular engineering approach, the antigen density is tuned from 13.6% to 70.3%. A systematic modulation reveals an optimal adjuvanticity at a constant antigen density for maximum anti‐tumor CD8 + T cell response, and vice versa, using the model antigen SIINFEKL. The M13 phage‐based nanovaccine induces durable memory immunity lasting over a year. In addition, a 24‐fold increase in neoantigen‐specific CD8 + T cell frequency is achieved when increasing both the adjuvanticity and antigen density. Furthermore, when combined with anti‐PD‐1 therapy, the M13 phage‐based personalized vaccine eradicates established MC‐38 tumors in 75% of treated animals and they develop 100% resistance against tumor invasion when challenged 5 months after treatment. These findings establish M13 phage as a powerful and versatile nanovaccine platform with transformative potential for personalized cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cancer VaccinesBacteriophage M13Precision MedicineNanoparticlesAnimalsCD8-Positive T-LymphocytesMiceHumansCell Line, TumorNeoplasmsFemaleNanovaccines

Stichwörter der Autor:innen

M13 bacteriophagebiomaterialscancer immunotherapynanovaccinepersonalized cancer vaccine

Substanzen

Cancer VaccinesNanovaccines

Autor:innen und Institutionen

  • The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Department of Brain and Cognitive Sciences, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Department of Nuclear Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Biopolymers Core Lab, The David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
  • Department of Materials Science and Engineering, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.

ORCID-Profile: Shengnan Huang, Mantao Huang, Angela M Belcher

Förderung

  • NCI NIH HHS
  • Koch Institute Frontier Research Program
  • Defense Advanced Research Projects Agency
  • Marble Center for Cancer Nanomedicine
  • National Cancer Institute

Zitieren

APA

Huang, S., He, Y., Madow, A., Peng, H., Griffin, M., Qi, J., Huang, M., Amoroso, H., Abrashoff, R., Heldman, N., & Belcher, A. M. (2025). A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer Vaccine and Therapy. Advanced Materials, 37(43). https://doi.org/10.1002/adma.202510229

Vancouver

Huang S, He Y, Madow A, Peng H, Griffin M, Qi J, et al. A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer Vaccine and Therapy. Advanced Materials. 2025;37(43). doi:10.1002/adma.202510229

BibTeX
@article{Huang2025,
  author = {Huang, Shengnan and He, Yanpu and Madow, Allison and Peng, Huaiyao and Griffin, Mirielle and Qi, Jifa and Huang, Mantao and Amoroso, Heather and Abrashoff, Riley and Heldman, Nimrod and Belcher, Angela M},
  title = {A Programmable Nanovaccine Platform Based on M13 Bacteriophage for Personalized Cancer Vaccine and Therapy},
  journal = {Advanced Materials},
  year = {2025},
  volume = {37},
  number = {43},
  doi = {10.1002/adma.202510229}
}
Kostenlos starten →